Sonde Respiratory Portal Available to Developers

RNS Number : 0583F

PureTech Health PLC

12 November 2020

 

12 November 2020

PureTech Health plc

PureTech Founded Entity Sonde Health Launches Self-Serve API that Detects Symptoms of Respiratory Disease from Changes in Voice

PureTech Health plc (LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercialising highly differentiated medicines for devastating diseases, is pleased to note that its Founded Entity, Sonde Health, today announced the launch of a new Developer Portal that provides organisations with access to Sonde's advanced vocal biomarker-based health check technology. As part of the launch, Sonde has introduced a new self-serve API (application programming interface) and documentation to allow developers to quickly, easily, and autonomously integrate Sonde's voice-enabled respiratory symptoms checker into their own iOS and Android mobile applications.

The full text of the announcement from Sonde is as follows:

Sonde Health Launches Self-Serve API that Detects Symptoms of Respiratory Disease

from Changes in Voice

New Developer Portal enables any organisation to quickly, easily, and affordably embed vocal biomarker health detection and monitoring in its mobile apps

BOSTON-November 12, 2020-- Today, Sonde Health has revealed a new Developer Portal that provides any team access to build with the company's advanced vocal biomarker-based health check technology. As part of the launch, Sonde has introduced a new self-serve API (application programming interface) and documentation to allow developers to quickly, easily, and autonomously integrate Sonde's voice-enabled respiratory symptoms checker into their own iOS and Android mobile applications.

Built on research from over 1 million voice samples and 80,000 individuals, Sonde's health condition monitoring technology uses advanced audio signal processing and machine learning to sense and analyse subtle changes in the voice due to changes in a person's physiology. With a 6-second voice sample, the platform detects with more than 70% accuracy symptoms such as coughing, shortness of breath, and chest tightness or pain, which are found in several respiratory diseases. Because Sonde's health check only takes a few seconds to administer and results are delivered in real-time over most mobile devices, scaled daily screening of large populations can be achieved to reduce the spread of respiratory illnesses, such as COVID-19 or influenza.

Now, this technology is officially available on a self-serve basis to developers and organisations of all sizes worldwide. Through Sonde Health's Developer Portal, software engineers can quickly access all the documentation, code snippets, and tools needed to give their users a unique and objective way to detect respiratory conditions, including asthma, COPD, COVID-19, and influenza from just seconds of voice.

"At Sonde, we're building products and technologies that empower people to proactively understand and manage their health, and we want to share them with the world," said David Liu, CEO for Sonde Health. "We created the Developer Portal and self-serve API to spur innovation outside of Sonde so more people can benefit from our voice-enabled health check capabilities. We can't wait to see what new use cases are imagined to deliver actionable health data and insights to people."

Sonde's API platform is HIPAA compliant and allows any organisation to utilize Sonde vocometers to collect, measure, and score (on a scale of 0-100) voice recordings for symptoms of respiratory disease within their own applications. Developers can also incorporate demographic or health-based questions (such as age, how is your cough today, etc.) into the workflow to better tailor the resources and recommendations their app serves users.

For instance, the technology is being used today alongside a CDC-informed COVID-19 symptoms questionnaire and temperature reading within the Sonde One COVID-19 symptom monitoring app. The Developer Portal and its self-serve capabilities increase the potential reach, speed-to-market, and adoption of Sonde's current and future voice-based health check APIs.

With a credit card and for as little as $0.15 per health check, healthcare providers and remote health monitoring companies, for example, can integrate Sonde's vocal biomarker technology into their patient-facing apps to monitor respiratory health trends, catch symptoms early, and connect patients with provider resources if needed. By making all the required documentation and tools available within the portal, Sonde eliminates unnecessary delays and enables organisations to start testing and integrating the technology into their own software in less than a day.

Building on Sonde's API is fast, easy, and free to get started. Simply visit Sonde Health's Developer Portal and register with an email address. Organisations that require higher health check volumes, customized support, and reporting can speak with Sonde's sales team at [e-mail].

About Sonde Health

Leveraging over 1 million voice samples from 80,000+ individuals, Sonde Health's proprietary voice-based technology platform detects symptoms of health conditions - like depression and respiratory disease -- from changes in voice. Using advanced audio signal processing and machine learning, Sonde senses and analyses subtle vocal changes due to changes in a person's physiology to provide early health detection and monitoring.

Sonde One, its health screening app, helps large organisations to execute a daily population screening regimen that helps reduce the spread of COVID-19, comply with government mandates, and return to work safely. Sonde also has broad intellectual property coverage worldwide and licenses its technology through its API platform. www.sondehealth.com  

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to discovering, developing and commercialising highly differentiated medicines for devastating diseases, including intractable cancers, lymphatic and gastrointestinal diseases, central nervous system disorders and inflammatory and immunological diseases, among others. The Company has created a broad and deep pipeline through the expertise of its experienced research and development team and its extensive network of scientists, clinicians and industry leaders. This pipeline, which is being advanced both internally and through PureTech's Founded Entities, is comprised of 24 products and product candidates, including two that have received US Food and Drug Administration (FDA) clearance and European marketing authorisation. All of the underlying programmes and platforms that resulted in this pipeline of product candidates were initially identified or discovered and then advanced by the PureTech team through key validation points based on the Company's unique insights into the biology of the brain, immune and gut, or BIG, systems and the interface between those systems, referred to as the BIG Axis.

For more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh.

Forward Looking Statement

This press release contains statements that are or may be forward-looking statements, including statements that relate to the Gelesis' future prospects, developments, and strategies. The forward looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, our expectations regarding the potential of Sonde's Developer Portal and those risks and uncertainties described in the risk factors included in the regulatory filings for PureTech Health plc. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, neither the company nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

Contact: Investors	EU media
Allison Mead Talbot [phone] [e-mail]	Ben Atwell, Rob Winder [phone] [e-mail]

 

END

 

 

NRAZZMMMGZVGGZG